Glaukos Corporation $GKOS Shares Bought by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc increased its position in Glaukos Corporation (NYSE:GKOS) by 20.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,429 shares of the medical instruments supplier’s stock after acquiring an additional 8,645 shares during the period. Ensign Peak Advisors Inc owned approximately 0.09% of Glaukos worth $5,312,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Primecap Management Co. CA boosted its position in Glaukos by 50.0% during the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after purchasing an additional 609,523 shares in the last quarter. Inspire Advisors LLC acquired a new position in shares of Glaukos during the 2nd quarter worth $208,000. Creative Planning boosted its position in shares of Glaukos by 28.8% in the 2nd quarter. Creative Planning now owns 18,368 shares of the medical instruments supplier’s stock worth $1,897,000 after buying an additional 4,105 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Glaukos by 11.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,670 shares of the medical instruments supplier’s stock valued at $1,515,000 after acquiring an additional 1,475 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in Glaukos by 19.4% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 12,739 shares of the medical instruments supplier’s stock valued at $1,316,000 after acquiring an additional 2,069 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Glaukos

In related news, COO Joseph E. Gilliam sold 19,340 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the sale, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. This trade represents a 17.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.80% of the stock is currently owned by insiders.

Glaukos Price Performance

GKOS stock opened at $97.92 on Tuesday. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of -63.58 and a beta of 0.81. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $163.71. The stock’s fifty day simple moving average is $85.06 and its 200-day simple moving average is $91.51.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The firm had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same period in the prior year, the firm posted ($0.28) earnings per share. The business’s quarterly revenue was up 38.1% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on GKOS shares. Wells Fargo & Company upped their price target on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Citigroup increased their target price on Glaukos from $110.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Stifel Nicolaus set a $115.00 price target on Glaukos in a report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.08.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.